NCT06779071

Pivotal Clinical Trial to Evaluate the Efficacy and Safety After NPNP-001 Application in Patients with Knee Osteoarthritis.

A Multicenter, Randomized, Double-blinded, Active-controlled, Non-inferiority, Pivotal Clinical Trial to Evaluate the Efficacy and Safety in Pain Reduction After NPNP-001 Application in the Knee Joint of Patients with Knee Osteoarthritis

• Status: Enrolling By Invitation
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 260 (estimated)
• Sponsor: PharmaResearch Co.,Ltd · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to demonstrate non-inferiority and safety in pain reduction after NPNP-001 application in patients with knee osteoarthritis.

Conditions

• Knee Osteoarthritis

Interventions

Type	Name	Description
DEVICE	NPNP-001	Description: NPNP-001 2ml per injection, once a week for 3 injections. Placebo(saline) 2ml per injection, once a week for 2 injections.
DEVICE	Conjuran	Description: Conjuran 2ml per injection, once a week for 5 injections.

Timeline

• Start date: 2025-01-08
• Primary completion: 2025-05-01
• Completion: 2026-06-01
• First posted: 2025-01-16
• Last updated: 2025-01-20

Locations

1 site across 1 country: South Korea